XML 17 R8.htm IDEA: XBRL DOCUMENT v3.25.2
Insider Trading Arrangements
 3 Months Ended
Jun. 30, 2025
shares
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement

Trading arrangement

During the quarter ended June 30, 2025, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K for the purchase or sale of our securities, except as set forth below:

Name and Title

Type of Plan

Adoption or Termination Date

Plan Start Date

Plan End Date

Aggregate Number of Securities to be Sold

Description of Trading Arrangement

Lara Sullivan, M.D.
President, Chief Executive Officer and Chief Medical Officer

Rule 10b5-1 trading arrangement

Terminated on June 24, 2025

March 26, 2025

December 31, 2025

513,000

Sales of shares intended to satisfy the affirmative defense of Rule 10b5-1(c)

Lara Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer

Rule 10b5-1 trading arrangement

Adopted on June 24, 2025

12/24/2024

08/28/2026

411,845

Sales of shares intended to satisfy the affirmative defense of Rule 10b5–1(c)

 
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
Lara Sullivan [Member]  
Trading Arrangements, by Individual  
Name Lara Sullivan
Title M.D.President, Chief Executive Officer and Chief Medical Officer
Rule 10b5-1 Arrangement Terminated true
Termination Date June 24, 2025
Expiration Date December 31, 2025
Aggregate Available 513,000
Lara Sullivan [Member]  
Trading Arrangements, by Individual  
Name Lara Sullivan
Title M.D., President, Chief Executive Officer and Chief Medical Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date June 24, 2025
Expiration Date 08/28/2026
Aggregate Available 411,845